Literature DB >> 10728619

Evaluating GA733-2 mRNA as a marker for the detection of micrometastatic breast cancer in peripheral blood and bone marrow.

X Y Zhong1, S Kaul, A Eichler, G Bastert.   

Abstract

The GA733-2 gene encodes the epithelial glycoprotein 40, a homophilic cell-cell adhesion molecule, which is expressed on the surface of epithelial cells and associated with a variety of carcinomas, e.g. breast, colorectal and lung carcinomas. To test if it could serve as a tumor marker, we have analysed the expression of GA733-2 in bone marrow (BM) and peripheral blood (PB) from healthy donors, and of patients with haematological malignancies or breast cancer using reverse transcriptase-polymerase chain reaction (RT-PCR). The GA733-2 nested PCR was positive in 100% (8/8) of BM and 40% (16/40) of PB from healthy donors, in 100% (33/33) of BM from patients with breast cancer who had no evidence of distant metastases and also in BM and PB from patients with haematological malignancies. GA733-2 mRNA is not specific as a marker for the detection of breast cancer cells in BM and PB.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10728619     DOI: 10.1007/s004040050251

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  8 in total

1.  Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood [corrected].

Authors:  Michael Mitas; Loretta Hoover; Gerard Silvestri; Carolyn Reed; Mark Green; Andrew T Turrisi; Carol Sherman; Kaidi Mikhitarian; David J Cole; Mark I Block; William E Gillanders
Journal:  J Mol Diagn       Date:  2003-11       Impact factor: 5.568

Review 2.  Clinical relevance associated to the analysis of circulating tumour cells in patients with solid tumours.

Authors:  María José Serrano Fernádez; Juan Carlos Alvarez Merino; Iñigo Martínez Zubiaurre; Ana Fernández García; Pedro Sánchez Rovira; José Antonio Lorente Acosta
Journal:  Clin Transl Oncol       Date:  2009-10       Impact factor: 3.405

3.  The added value of circulating tumor cells examination in ovarian cancer staging.

Authors:  Katarina Kolostova; Rafał Matkowski; Marcin Jędryka; Katarzyna Soter; Martin Cegan; Michael Pinkas; Anna Jakabova; Jiri Pavlasek; Jan Spicka; Vladimir Bobek
Journal:  Am J Cancer Res       Date:  2015-10-15       Impact factor: 6.166

4.  Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients.

Authors:  Eva Obermayr; Fatima Sanchez-Cabo; Muy-Kheng M Tea; Christian F Singer; Michael Krainer; Michael B Fischer; Jalid Sehouli; Alexander Reinthaller; Reinhard Horvat; Georg Heinze; Dan Tong; Robert Zeillinger
Journal:  BMC Cancer       Date:  2010-12-03       Impact factor: 4.430

Review 5.  Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancer.

Authors:  Xianliang Cheng; Lei Zhang; Yajuan Chen; Chen Qing
Journal:  J Ovarian Res       Date:  2017-11-13       Impact factor: 4.234

6.  Identification of circulating tumour cells in early stage breast cancer patients using multi marker immunobead RT-PCR.

Authors:  Michael P Raynor; Sally-Anne Stephenson; Kenneth B Pittman; David C A Walsh; Michael A Henderson; Alexander Dobrovic
Journal:  J Hematol Oncol       Date:  2009-06-05       Impact factor: 17.388

7.  One-step detection of circulating tumor cells in ovarian cancer using enhanced fluorescent silica nanoparticles.

Authors:  Jin Hyun Kim; Hyun Hoon Chung; Min Sook Jeong; Mi Ryoung Song; Keon Wook Kang; Jun Sung Kim
Journal:  Int J Nanomedicine       Date:  2013-06-21

8.  Gene expression of circulating tumour cells in breast cancer patients.

Authors:  E Bölke; K Orth; P A Gerber; G Lammering; R Mota; M Peiper; C Matuschek; W Budach; E Rusnak; S Shaikh; B Dogan; H B Prisack; Hans Bojar
Journal:  Eur J Med Res       Date:  2009-09-28       Impact factor: 2.175

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.